portrait of smiling man stading in wooded areaportrait of smiling man stading in wooded areablue triangle graphic

Great Science
Deep Compassion
Real Impact

Leveraging our long-standing neuroscience
expertise to develop medicines that
make a difference.

Discover Alkermes

Featured News

February 15, 2024

Alkermes plc Reports Financial Results for the Fourth Quarter and Year Ended Dec. 31, 2023 and Provides Financial Expectations for 2024

Read more

January 03, 2024

Alkermes Announces Topline Results From Long-Term, Open-Label Safety and Durability of Treatment Effect Study of LYBALVI® (olanzapine and samidorpha...

Read more

December 14, 2023

Alkermes plc Announces Agreement to Sell Athlone, Ireland Facility to Novo Nordisk

Read more

See all press releases

Smiling woman standing in hallway at Alkermes office.

Action for Good

More than 200 Alkermes employees recently took time out of their normal work day to contribute their time and talents to a variety of local Massachusetts nonprofit organizations as part of our fifteenth Alkermes in Action employee volunteer day. 

Read about the program

Inspiring Programs

Now in its seventh year, we are proud of the impact the Alkermes Inspiration Grants® program has made in support of creative and innovative programs designed to make a difference for patient communities. Visit the program page to learn about the latest group of grant recipients.

Visit the program page

Man standing in lab coat with mask on in laboratory area at Alkermes.

Man sitting in front of green background at Alkermes office.

Driven by Passion

Alkermes employees work with urgency -- in the laboratory, in the clinic and in the community -- seeking to make a meaningful difference for people living with complex and difficult-to-treat diseases. For many of our employees, this work is part of their personal mission to help patients, families and communities. 

Learn more about our culture

R&D Pipeline 

We apply our deep neuroscience expertise to develop medicines designed to help people living with complex and difficult-to-treat psychiatric and neurological disorders. We are currently focused on developing these investigational candidates.

Learn more about our pipeline

  • Discovery
  • Preclinical
  • Phase 1
  • Phase 2
  • Phase 3
  • Neuroscience

    • Olanzapine and samidorphan - Schizophrenia or Bipolar I Disorder (pediatric)

    • ALKS 2680 - Narcolepsy

    • Orexin Agonists - Non-Orphan Indications

These programs are investigating treatments or indications that have not received approval from a health authority. The information presented is not intended to convey conclusions of safety or efficacy. There is no guarantee that the outcome of these studies will result in approval by a health authority. 

Last updated: November 2023


  We dare for progress every day. 
We take pride in our unique and compassionate spirit.
Our shared mission to make a real impact for others drives our purpose.
With collaboration at our core, we believe that anything is possible.

Working at Alkermes

Man with mask sitting in meeting talking to colleague at Alkermes.blue triangle graphic

Neurological and psychiatric disorders strike people at the core of who they are and impact many facets of their lives. We are driven to help advance innovation in hopes of providing additional treatment options for people living with complex and often difficult-to-treat diseases.